MedTrace Logo

Inhaled Steroid Reduces Systemic Inflammation in COPD

NCT00175565 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-07-28

No results posted yet for this study

Summary

Systemic inflammation is present in chronic obstructive pulmonary disease (COPD), which has been linked to cardiovascular morbidity and mortality. We determined the effects of oral and inhaled corticosteroids on serum markers of inflammation in patients with stable COPD.

Conditions

Interventions

DRUG

inhaled fluticasone 500 mcg b.i.d.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Paul Man, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2003-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00175565 on ClinicalTrials.gov